# Symptom Adapted Therapy in GERD Patients

> **NCT00343161** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 441 (—)

## Conditions studied

- Gastroesophageal Reflux Disease

## Interventions

- **DRUG:** esomeprazole
- **DRUG:** Gelusil-Lac (Aluminum hydroxide gel,magnesium trisilicate)

## Key facts

- **NCT ID:** NCT00343161
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2007-08
- **Final completion:** 2007-08
- **Target enrollment:** 441 (—)
- **Last updated:** 2011-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00343161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00343161, "Symptom Adapted Therapy in GERD Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00343161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*